炎症体
上睑下垂
目标2
2型糖尿病
胰岛素抵抗
先天免疫系统
医学
炎症
NLRC4型
免疫系统
半胱氨酸蛋白酶1
免疫学
糖尿病
胰岛素
生物信息学
癌症研究
生物
内科学
内分泌学
作者
Shen Lu,Yanrong Li,Zhaojun Qian,Tiesuo Zhao,Zhiwei Feng,Xiaogang Weng,Lili Yu
标识
DOI:10.3389/fimmu.2023.1052756
摘要
The inflammasome is a protein complex composed of a variety of proteins in cells and which participates in the innate immune response of the body. It can be activated by upstream signal regulation and plays an important role in pyroptosis, apoptosis, inflammation, tumor regulation, etc. In recent years, the number of metabolic syndrome patients with insulin resistance (IR) has increased year by year, and the inflammasome is closely related to the occurrence and development of metabolic diseases. The inflammasome can directly or indirectly affect conduction of the insulin signaling pathway, involvement the occurrence of IR and type 2 diabetes mellitus (T2DM). Moreover, various therapeutic agents also work through the inflammasome to treat with diabetes. This review focuses on the role of inflammasome on IR and T2DM, pointing out the association and utility value. Briefly, we have discussed the main inflammasomes, including NLRP1, NLRP3, NLRC4, NLRP6 and AIM2, as well as their structure, activation and regulation in IR were described in detail. Finally, we discussed the current therapeutic options-associated with inflammasome for the treatment of T2DM. Specially, the NLRP3-related therapeutic agents and options are widely developed. In summary, this article reviews the role of and research progress on the inflammasome in IR and T2DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI